Surface modifications of poly(lactide-co-glycolide) microparticles with different polycationic electrolytes have mainly been studied for conjugation to antigens and/or adjuvants. However, the in vivo immunological effects of using surface charged particles have not been address yet. In this study, microparticles were coated or not with protamine, a cationic and arginine-rich electrolyte that confers microparticles with a positively surface charge. We then evaluated the potential of protamine-coatings to assist the induction of immune responses in mice. Interestingly, enhanced antibodies and T-cell responses were observed in mice treated with the coated particles. In vitro studies suggested that the improved immunological performance was mediated by an increased uptake. Indeed, protamine-coated particles that carried a plasmid were even internalised into non-phagocytic cells and to cause their transfection. These results open the way for further research into a novel technology that combines the use protamine for facilitated cell penetration of that and biodegradable microparticles for prolonged antigen or drug release.
Characteristics and application of the different groups of formulations used in the current the study.
The second group of microparticles, with and without protamine coating, contained pGFP. They were prepared for analysing particle uptake by cells and particle-mediated cell transfection. Briefly, pGFP (0.7 mg) was dissolved in Tris-EDTA (TE) buffer (0.2 ml) and emulsified in PLGA (0.2 g) dissolved in DCM (5%, w/w). The subsequent steps for microparticle formation were as described above.
The third group of microparticles, with and without protamine coating, was loaded with OVA for subsequently analyses of T-cell responses. Briefly, OVA (50 mg) was dissolved in PBS (0.8 ml), emulsified in PLGA (1 g) dissolved in DCM (5%, w/w), and further processed as described above.
Particle size and zeta potential measurements
Microparticle size distributions were determined by laser light diffraction (Mastersizer X, Malvern Instruments Malvern, United Kingdom) with a suspension of approx. 
Determination of antigen content in the microparticles
Triplicates of approx. 7 mg PLA2-or pGFP-containing particles were dissolved in 0.5 ml chloroform and the protein or the plasmid extracted from the organic phase by mixing with 0.2 ml Tris-HCl buffer and subsequent centrifugation at 3000 rpm for 3 min. The content of plasmid DNA from the pGFP-MPs was analysed by the PicoGreen quantification kit (Invitrogen AG, Switzerland) following the manufacturer instructions.
The PLA2 concentration in the aqueous extract was analysed by an ELISA inhibition assay. Briefly, 60 μl of the Tris-HCl phase containing the extracted PLA2 was mixed in a 96-well plate with 60 μl human anti-PLA2 serum diluted (1:25) in phosphate-buffered saline containing 0.05% Tween20 and 2.5% skimmed dry milk (PBSTM). In parallel, serial dilutions of PLA2 were mixed with sensitised serum and utilised as a standard for quantification. After 2 h of incubation at 37 °C, 100 μl of each sample was transferred to an ELISA plate that was pre-coated with 5 μg/ml PLA2 at 4 °C overnight and subsequently blocked with PBSTM at room temperature for 1 h. After 2 h incubation at 37 °C, the plate was washed and incubated with horseradish peroxidase-conjugated anti-human IgG (BD Biosciences Pharmingen, San Diego, CA). The plate was washed and developed with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogen phosphate and the absorption was read at 405 nm using a plate reader. The loading efficiency of PLA2 in the MP was calculated relative to the theoretical maximum loading value. For the quantification of OVA inside the MPs, OVA-containing particles were dissolved in 0.1 M NaOH and 5% SDS overnight at room temperature and then measured by the BCA protein assay (Pierce Biotechnology, USA).
Internalisation of pGFP-loaded PLGA microparticles (MP) by HEK cells
The role of the protamine in the particle uptake by cells was studied by measuring the transfection of Human Embryonic Kidney (HEK) cells upon incubation with microparticles containing the plasmid pGFP, taking use of the fact that positive transfection would necessarily imply uptake of the plasmid containing particle by the cell; preliminary studies with FITC or coumarin-loaded particles were also done, but this did not allow to clearly distinguish between internalised particle and particle attached to 
In vitro analysis of T-cell stimulation
Murine dendritic cells were isolated from BALB/c bone-marrow and grown in 10 cm Petri dishes at a density of 1 × 10 6 cell/ml in 10 ml RPMI-1640 complete media containing 20 ng/ml of granulocyte macrophage colony stimulating factor (GM-CSF) and 10 ng/ml of IL-4 (Immunotools, Friesoythe, Germany). After 2 and 4 days, the culture medium was replaced by fresh medium containing GM-CSF and IL-4. After 6 days, immature
DCs were collected and seeded at 1 × 10 5 cells per well in a 96-well plate and then pulsed for 3 h at 37 °C and 5% CO 2 with escalating amounts of OVA-containing microparticles, empty microparticles (1 or 100 μg) or aqueous OVA (10 or 100 μg/ml).
After three washing steps, the cells were co-cultured with splenocytes ( 
Immunisation of mice
To evaluate the potential of the microparticles to stimulate T-cell responses in vivo, 6- 
Flow cytometry
Intracellular IFN-γ was assessed in blood of the OT-II mice injected with 1 mg of OVA-MP or OVA-MP/protamine. After lysis of the erythrocytes with hypotonic Red Blood Cell Lysis Buffer (Sigma-Aldrich), splenocytes were stimulated in vitro with soluble OVA (10 μg/ml) and brefeldin A (10 μg/ml) (Sigma-Aldrich) for 3 h at 37 °C and 5% CO 2 . For FACS staining, the cells were washed several times, incubated with anti-CD16/CD32 for Fc-receptor blocking (5 min), and stained with anti-CD44-FITC and anti-CD4-APC antibodies for 30 min. Cells were then fixed with 1% paraformaldehyde for 10 min and subsequently stained with anti-IFN-γ-PE in PBS/0.5% saponin for 30 min. All stainings were done in PBS/2% FCS at 4 °C, unless specified otherwise, and all antibodies were purchased from BD Pharmingen (Franklin Lakes, NJ, USA). Samples were measured on a FACSCalibur flow cytometer (BD Bioscience, San Jose, CA, USA), and data was analysed using FlowJo software (Ashland, OR, USA).
Antibody determination by enzyme-linked immunosorbent assay (ELISA)
For detection of PLA2 antibodies, microtitre 96-well plates (Nunc Maxisorb, Wiesbaden, Germany) were coated with 5 μg/ml PLA2 in carbonate buffer at 4 °C overnight. The plates were blocked with 2.5% skinned dry milk in phosphate-buffered saline containing 0.05% Tween 20 (Serva, Heidelberg, Germany) (PBSTM) for 1 h. Then, serial dilutions of individual mice sera in PBSTM were incubated in the plates for 2 h. Next, the plates were incubated with 1 μg/ml biotinylated goat anti-mouse IgG1 or IgG2a (BD Bioscience Pharmingen) in PBSTM for 2 h. Subsequently, plates were incubated with a 1:1000 dilution of streptavidin-conjugated horseradish peroxidase (BD Pharmingen) for 1 h and developed with the enzyme substrate 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (Sigma-Aldrich) in 1 M sodium dihydrogenphosphate. The endpoint optical density was measured at 405 nm after 20 min incubation using a microplate reader Model 550 (BioRad, Hercules, CA, USA). All steps were intercepted by washings with PBST.
Results

Microparticle characterisation
Three different groups of microparticles, all with and without protamine coating, were prepared ( Table 1 ). The formulations with encapsulated pGFP, named pGFP-MP or pGFP-MP/protamine, had a very similar size distribution. Fifty percent of the particles were smaller than 3.2 μm or 3.5 μm, respectively. For both OVA-and PLA2-containing formulations, the size of the protamine-coated particles was larger than that of the noncoated particles. This was most evident for the OVA-containing microparticles, where 50% of the OVA-MP/protamine were smaller than 7.2 μm as compared to 3.2 μm for the non-coated particles ( Table 1) . Independent of the encapsulated antigen, the zeta potential of the protamine-coated microparticles was, as expected, positive (+ 11 to + 65 mV), which is due to the polycationic charge of protamine; on the contrary, the non-coated particles had negative zeta potential (ranging from − 11.8 to − 2.4 mV).
In vitro internalisation of pGFP-loaded microparticles
To examine the effect of the protamine coating on the internalisation of the microparticles, HEK cells were incubated for 4 h with different amounts of pGFPcontaining particles, with or without protamine coating. Transfection of the cells was assessed as a measure for particle internalisation by fluorescence microscopy. As illustrated in Fig. 1A , only protamine-coated particles were able to transfect HEK cells.
The transfection was dose-dependent, as the efficacy increased with the amount of particles used in the culture (Fig. 1B) and the frequency of transfected cells was approx.
0.4% (0.1-1.0%). reveals that the protamine coating enhanced the IL-2 secretion in a dose-dependent manner and with a 10-fold higher sensitivity than the uncoated particles.
Correspondingly, the protamine-coated particles also showed a 10-fold increased capacity to stimulate the secretion of IFN-γ (Fig. 2B) as well as the proliferation of antigen-specific T cells (Fig. 2C ). This effect of protamine was also observed when compared to stimulation of splenocytes using DCs pulsed with soluble OVA. Cells stimulated with 100 μg/ml or 10 μg/ml OVA solution produced very low or even undetectable levels of IL-2, and moderate and concentration-dependent T-cell proliferation. Unloaded microparticles, with or without the protamine coating, did neither stimulate IL-2 production nor lymphocyte proliferation (data not shown). 
H] thymidine incorporation (C). Data was analysed by Two Way
ANOVA with Bonferroni post test (***p < 0.0001; **p < 0.01).
Stimulation of T-cell responses in mice
The capacity of microparticles to enhance the induction of T-cell responses in vivo was evaluated in transgenic OT-II mice. Animals were injected with 1 mg of either uncoated or protamine-coated microparticles containing OVA protein, OVA-MP or OVA-MP/protamine, and T-cell responses were assessed by measuring the activated CD4 T cells producing IFN-γ after 7, 14 and 21 days. Mice injected with OVA-MP/protamine induced higher frequencies of IFN-γ producing CD4 T cells at all time points as compared to mice that received OVA-MP (Fig. 3) . As early as day 7 (Fig. 3A ) the protamine-coated microparticles induced significant levels of IFN-γ producing cells, in contrast to the uncoated microparticles that needed an additional week to raise a moderate response. At day 14, less than 2% of the cells from the mice immunised with the uncoated particles were IFN-γ producing CD4 T cells as compared to 3% achieved with the protamine-coated particles (Fig. 3B) . Maximal response was attained with both formulations at day 14 after the injection (Fig. 3B) . Untreated mice were used to determine the background levels of IFN-γ in the OT-II mice. 
Stimulation of B-cell responses in mice
To evaluate the effect of the protamine coating on the stimulation of B-cell responses, CBA/J mice were immunised with microparticles containing the major bee venom allergen PLA2. The antibody responses were determined at 28, 55 and 84 days after the first injection. After the first injection, the protamine-coated particles induced a weak PLA2-specific IgG1 response, while the uncoated particles failed to do so, as measured 28 days after the priming (Fig. 4A) . When a second dose was administered at day 28, the IgG1 response was strongly boosted by the protamine-coated particles, but not by the uncoated particles. The IgG1 levels remained high for at least 84 days. Two injections were required to induce a detectable IgG2a response; and again, the response, although weak, was stronger in mice immunised with the protamine-coated particles (Fig. 4B) . Test (***p < 0.0001; **p < 0.01; *p < 0.05).
For assessing whether the observed benefit of the protamine coating persisted in the presence of an additional adjuvant, the two PLA2-loaded microparticle formulations were admixed with immune stimulatory CpG prior to injection. The previously observed Th2-biased response was shifted in the presence of CpG towards Th1, with both PLA2-MP and PLA2-MP/protamine ( Fig. 4C and D) . The IgG1 levels increased for both formulations, but the protamine-coated particles again stimulated stronger responses than the uncoated particles.
Discussion
Microparticles of PLGA have been widely studied for their use as drug and antigen delivery systems [3] , [31] and [6] . These particulate systems are able to deliver drugs or antigens such as DNA, proteins, and peptides over prolonged periods of time, and induce strong immune responses against encapsulated antigens [13] , which makes them attractive candidates for vaccine development.
Stability issues with encapsulated biologicals have led to an alternative method for associating antigens and DNA with PLGA microparticles, namely by adsorbing the bioactive materials onto the surface of anionic or cationic particles [16] and [18] . One potential reason for the difference between protamine-coated and protamine-free particles with respect to their interaction with APCs could be differences in the particles size distribution of the formulations. In this study, the size distribution of the uncoated OVA-containing microparticles was ideal for uptake, since 90% of the particles were smaller than 6.4 μm, and only particles smaller than 5-10 μm have been shown to be efficiently taken up by antigen-presenting cells [7] and [33] . However, as the protaminecoated microparticles had a broader size distribution than the uncoated ones, with only 50% of the particles being smaller than 7.2 μm, the size cannot explain the differences in vitro and in vivo immune responses.
Besides particle size, particle surface charge may also influence the interaction with APCs. Positively charged particles are more likely to bind to the negatively charged cell surfaces, and thereby facilitate uptake and stimulation of immune responses. Indeed, cationic microparticles have been reported to enhance phagocytosis by DCs and macrophages in comparison with unmodified particles [34] , [35] and [36] . The mechanism suggested for the enhanced uptake in those studies is the electrostatic attraction between the positively charged microparticles and the negatively charged cell surface mediating binding and subsequent internalisation. In addition to its positive charge at physiological pH, protamine specifically contains arginine-rich sequences, which share structural similarity with certain viral proteins such as the Tat from the Human Immunodeficiency Virus (HIV-1) or the VP22 from the Herpes Simplex Virus, both of which possess protein translocation activity [37] , [38] and [39] . These sequences of basic amino acids mediate the penetration of viruses into cells in an energyindependent manner [40] ; thus, these so-called cell-penetrating peptides or peptidic moieties appear to be particularly good candidates as transporters for drug delivery.
While the cell-penetrating property of Tat peptides have been extensively studied [41] , [42] and [43] , the potential of protamine to carry cargos across the cell membrane is less recognised. However, in 2005, two independent groups reported that protamine can act as an efficient membrane-translocating peptide both in vitro [44] and in vivo [44] and [45] . Park et al. showed that a protein toxin conjugated to protamine was able to translocate into cells in vitro, resulting in the inhibition of tumour growth in vivo. It was also reported that Tat-carrying [46] and protamine-carrying [44] iron nanoparticles were readily internalised by cells. Moreover, Tat-liposomes of 200 nm showed potential for intracellular gene delivery in vitro and in vivo [47] and [48] . These experiments suggest that the improved immunological performance of protamine-coated antigen-containing PLGA microparticles was mediated by the cell-penetrating properties of the arginine-rich protamine. We could confirm this by testing the transfection of bone-marrow DCs using microparticles containing a plasmid coding for GFP (data not shown). However, to test this hypothesis in a more stringent model, we also tested the uptake in and transfection of non-phagocytic HEK cells. Indeed, protamine-coated particles were capable to transfect the HEK cells, whereas uncoated particles did not possess this capacity. The same was observed when testing the particles on non-phagocytic melanoma cells (no shown). As the size distribution of the tested formulations was almost identical (± 0.3 μm), the observed differences must be ascribed to protamine and its ability to translocate the microparticles intracellularly.
Although, there is certain controversy in the literature concerning the translocation mechanisms of cell-penetrating peptides, recent data suggests more than one mechanism. Studies using Tat-nanoparticles or Tat-liposomes suggest that the translocation mechanism occurs via energy-dependent macropinocytosis [43] and [49] , whereas peptide-conjugated small molecules penetrate via electrostatic interactions and do not seem to depend on energy [50] . The exact mechanism of protamine-mediated penetration of microparticles into non-phagocytic cells remains to be clarified. 
